abstract |
The present disclosure is directed to novel methods for detecting tissue damage, graft- versus-host disease (GVHD), microbial infections, presence of a tumor, and loss of engraftment in a subject using cell-free DNA (cfDNA) profiling. The methods of the disclosure are in part based on the recognition that damaged tissues, microbes during an infection, tumors, and donor cells (e.g., in a hematopoietic cell transplantation) shed small fragments of cfDNA into blood circulation. |